Treat lab data as a strategic asset.
Look beyond isolated transactions. Longitudinal lab findings can help teams understand clinical patterns and build populations around the biology that matters to their question.
Lab Data Summit 2026 · Event insights
The next era of health
starts with better
use of lab data.
April 9, 2026W Hotel · Philadelphia, PA
One room. A shared challenge. Leaders across life sciences, diagnostics, and technology came together to explore how fragmented lab information can become a strategic asset for precision health.
Lab dataTechnologyPatient impactLife sciencesConnected by possibility
The purpose behind the platform
Every data challenge
leads back to a person.
Unlocking the Power of Data to Improve Health.
The inaugural Lab Data Summit brought together perspectives from pharmaceutical companies, labs, data organizations, and technology teams. Their work spans different disciplines, but the questions converge: How do we recognize a meaningful signal? How do we connect it to the right context? And how do we make it useful when a decision matters?
Lab data adds a distinctive dimension to that work: measured findings that can help reveal biological change, characterize disease, and follow clinical patterns over time. Realizing its value requires more than access to individual results. It requires the infrastructure, interpretation, and partnerships that turn those results into trusted intelligence.
Three ideas to carry forward
Better foundations.
More meaningful action.
Across discussions of AI, precision medicine, and commercial execution, three priorities emerged.
Build trust into the foundation.
Aggregation, harmonization, deduplication, and clear provenance shape the usefulness of everything downstream—from an analytic model to an HCP signal.
Design for the people using it.
Make insights interpretable, relevant, and usable within real workflows. Feedback from clinical and field teams can help improve the signals they rely on.
Solving the “messy middle”
Intelligence is only as strong as the infrastructure beneath it.
The Summit’s three-layer framework made a recurring challenge visible: lab sources can describe related findings in different formats, with overlapping records and inconsistent identifiers.
The middle layer is where those differences must be resolved. Prognos harmonization and enrichment help turn varied source records into more consistent, clinically meaningful information for analysis and engagement.
Discuss your data foundation →Bring the sources together.
Lab results, biomarker findings, and available report detail from contributing sources.
Harmonize. Enrich. Connect.
Aggregation, common schemas, result interpretation, patient linkage, and deduplication help make the data usable.
The critical middle layerPut clinical context to work.
Inform patient finding, research, medical strategy, analytics, and relevant HCP engagement.
Where the foundation meets the need
Precision is practical.
And deeply personal.
Oncology and rare disease discussions brought the infrastructure challenge into focus: clinically meaningful detail must reach the people who can use it.
Oncology
Make complex biomarker information easier to act on.
Different testing methodologies and fragmented reporting can make the clinical picture difficult to interpret. The discussions emphasized clear reporting, testing visibility, and insights that fit community and specialist workflows.
- Understand testing patterns and available biomarker findings.
- Preserve the context behind a result, including the testing method.
- Make clinically relevant signals easier to interpret and use.
Rare disease
Help meaningful patterns become easier to recognize.
Rare disease expertise is often concentrated in specialized centers. Longitudinal patterns and provider context can help teams focus education and evaluate potential patient populations beyond those settings.
- Look for relevant patterns across available clinical history.
- Connect observed signals with provider and care context.
- Support awareness within local practices and referral networks.
From the discussions
A wider view of
what comes next.
The day explored the decisions that connect data strategy to execution. Expand a theme for a closer look.
AI readiness begins with data readiness.
Useful AI depends on the work beneath the model: resolving incomplete or conflicting records, understanding provenance, validating outputs, and maintaining appropriate human review. Adoption also depends on tools that help people do their work more effectively.
Patient linkage needs purpose and governance.
A broader patient view is valuable when it answers a defined question. Discussions emphasized more agile, use-case-specific data assembly, with privacy and governance built into linkage decisions.
Speed matters when the signal is useful.
Delivery cadence can change what a team is able to do with a finding. Timeliness must be paired with clinical relevance, deduplication, and clear interpretation so that faster delivery does not simply create more noise.
Transparency strengthens adoption.
Teams need to understand what a signal represents and where gaps remain. Clear expectations and a route for user feedback can help build confidence and improve the quality of insights over time.
Partnership connects the ecosystem.
Pharma, labs, data providers, and technology organizations each bring part of the solution. Shared standards and collaborative problem-solving can help connect those contributions around specific clinical and business needs.
Who spoke
The voices behind the conversation.
22 leaders from pharma, diagnostics, data, and technology joined us in Philadelphia on April 9, 2026 to share how lab data is shaping decisions across their organizations.
Fireside chat
From Lab Data to Breakthroughs: Scaling AI, Technology, and Trust Across Healthcare
Linda Fonseca
Chief Digital and Technology Officer
PfizerSundeep Bhan
Co-Founder, Chief Executive Officer
Prognos Health
Panel
From Insight to Impact: How Lab Data Powers Smarter Decisions Across Oncology, Rare Disease, and Commercial Execution
- Moderator
Chris Hayes
Executive Vice President, GM Sales and Business Development
Prognos Health Sophie Peoples
Sr. Director, Head of Oncology – Digital Data & Tech
GSKFayette Thackston
Precision Medicine Solutions
Pfizer OncologyThomas Lampron
Vice President, Oncology Global Marketing, New Products
Merck
Panel
Healthcare Data in the Age of AI: Promise, Progress, and Hard Truths
- Moderator
Jason Bhan, MD
Co-Founder, Chief Medical Officer
Prognos Health Gaurav Singal, MD
Physician, Advisor & Investor
Harvard Medical SchoolJeremy Foreman
Chief AI, Data & Analytics Officer, SVP
PfizerMiruna Sasu
Chief Data Officer
Novartis US
Panel
The Infrastructure of Identity: Constructing the 360-Degree Patient View
- Moderator
Dr. S. Yin Ho, MD, MBA
Health IT CEO, Entrepreneur, Board Director, Advisor, and Author
Chris Beggs
Senior Director, Patient Data Product & Strategy
IQVIAArnaub Chatterjee
President and GM of Life Sciences, Ecosystem, and Public Sector
DatavantPeter Portanova
Vice President, Data Partnerships
Veeva
Panel
Operationalizing Lab Data for High Impact in Oncology
- Moderator
Tom Neyarapally
CEO
Archetype Therapeutics Chris Chandy
Director, US Oncology Brands
AzurityLindsey Gasparini
Vice President, Oncology Data Solutions
NeoGenomicsToscha Love
Vice President, Life Sciences Commercial, AI Apps
Tempus AI
Panel
The New Rare Disease Playbook: Shortening the Diagnostic Odyssey
- Moderator
Steve Vitale
Vice President, Life Sciences
Prognos Health Gene Kelly
Executive Director, Medical Affairs
Stealth BioGrant Castor
Executive Vice President, Chief Business & Commercial Officer
Sentynl TherapeuticsTom Lo
Director, Business Development, Healthcare Analytics Solutions
Quest Diagnostics
The takeaway
The opportunity is to make more of the data we have—and make it matter for health.
The Summit reinforced a shared direction: invest in the foundation, preserve clinical meaning, and build around the people who need to use the intelligence. That is how lab data can become a more powerful resource across the life sciences ecosystem.
Continue the conversation
Help shape the next chapter.
Explore the 2027 Lab Data Summit and request an invitation to join the conversation.